- Home
- ELVN vs CLVT Comparison
ELVN vs CLVT Comparison
Compare ELVN & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | CLVT |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELVN | CLVT |
|---|---|---|
| Price | $27.41 | $2.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 7 |
| Target Price | ★ $41.00 | $3.22 |
| AVG Volume (30 Days) | 647.0K | ★ 7.6M |
| Earning Date | 06-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $40.06 | $2.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.30 | $1.66 |
| 52 Week High | $30.98 | $4.77 |
Technical Indicators
Market Signals| Indicator | ELVN | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 49.12 |
| Support Level | $18.89 | $1.66 |
| Resistance Level | $29.63 | $3.73 |
| Average True Range (ATR) | 1.61 | 0.18 |
| MACD | -0.34 | 0.05 |
| Stochastic Oscillator | 2.18 | 48.78 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.